CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 2.27B | 2.36B | 2.44B | 1.98B | 1.92B |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 12.15M | 7.02M | 6.18M | 5.95M | 9.88M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 377.00K | 400.00K | 400.00K | 3.89M | 3.50M |
| Total Current Assets | 2.29B | 2.37B | 2.45B | 1.99B | 1.93B |
|
|
|||||
| Total Current Assets | 2.29B | 2.37B | 2.45B | 1.99B | 1.93B |
| Net Property, Plant & Equipment | 226.91M | 233.66M | 240.85M | 247.58M | 255.49M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 8.51M | 9.44M | 9.41M | 9.40M | 9.71M |
| Total Assets | 2.56B | 2.65B | 2.73B | 2.27B | 2.25B |
|
|
|||||
| Total Accounts Payable | 20.59M | 11.31M | 13.65M | 11.14M | 11.80M |
| Total Accrued Expenses | 29.12M | 30.71M | 28.96M | 34.46M | 24.90M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 18.68M | 18.65M | 18.61M | 18.58M | 18.26M |
| Total Finance Division Other Current Liabilities | 72.57M | 72.24M | 75.06M | 84.95M | 64.00M |
| Total Other Current Liabilities | 72.57M | 72.24M | 75.06M | 84.95M | 64.00M |
| Total Current Liabilities | 140.96M | 132.90M | 136.29M | 149.12M | 118.96M |
|
|
|||||
| Total Current Liabilities | 140.96M | 132.90M | 136.29M | 149.12M | 118.96M |
| Long-Term Debt | 586.93M | 586.20M | 585.47M | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 174.21M | 178.90M | 183.56M | 188.17M | 192.77M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 6.24M | 6.22M | 5.95M | 6.14M | 17.60M |
| Total Liabilities | 908.34M | 904.22M | 911.26M | 343.43M | 329.33M |
|
|
|||||
| Common Stock & APIC | 3.94B | 3.91B | 3.89B | 3.86B | 3.73B |
| Retained Earnings | -2.27B | -2.16B | -2.07B | -1.95B | -1.82B |
| Treasury Stock & Other | -14.14M | -4.69M | -2.00M | 4.76M | 4.93M |
| Total Common Equity | 1.65B | 1.75B | 1.81B | 1.92B | 1.92B |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.65B | 1.75B | 1.81B | 1.92B | 1.92B |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.65B | 1.75B | 1.81B | 1.92B | 1.92B |
|
|
|||||